Hepatoprotective Effects of Imeglimin Are Associated With Preserved Mitochondrial Bioenergetics and Reduced Oxidative Stress in a Murine Cholestasis Model
- 7 August 2026
- journal article
- Published by Wiley in Hepatology Research
Abstract
Purpose: Biliary atresia is a cholestatic liver disease that causes persistent inflammation and reduces the hepatic reserve. New therapeutic concepts are crucial to improve native liver survival. We investigated whether imeglimin, a mitochondria‐targeting agent, has hepatoprotective effects on cholestatic liver disease using a murine bile duct ligation (BDL) model. Methods: BDL was performed in 4–5‐week‐old mice. After BDL, the mice received intraperitoneal imeglimin or vehicle injections. Sham‐operated mice received vehicle. Blood and liver samples were collected on days 7 and 14 for biochemical and histological analysis. Mitochondrial morphology was examined by transmission electron microscopy. Quantitative PCR and immunoblotting were performed for inflammation and mitochondrial stress markers. Metabolomic profiling was conducted using capillary electrophoresis–mass spectrometry. Transcriptome was analyzed by RNA sequencing. Seahorse assays, ATP quantification, and MitoSOX staining were used to evaluate mitochondrial function and oxidative stress. Results: Imeglimin improved survival after BDL, and reduced serum AST, ALT, and bilirubin levels. Tissue fibrosis and Col1a1 and Acta2 expression were attenuated in imeglimin‐treated livers. Glycolysis, amino acid metabolism, and mitochondrial electron transport activity were enhanced. Expression of genes associated with mitochondrial function, antioxidant defense, and metabolic regulation was upregulated. Mitochondrial morphology was preserved, and mitochondrial number and size increased. Imeglimin elevated oxygen consumption, extracellular acidification rates, and ATP levels of BDL mice livers, while reducing mitochondrial superoxide and oxidative protein modification by 4‐hydroxynonenal. Expression levels of Il1β , Il6 , and Tnf decreased. Conclusion: Imeglimin exerted hepatoprotective effects on BDL‐operated mice, which are associated with preserved mitochondrial bioenergetic function and reduced oxidative stress.Keywords
Funding Information
- Japan Society for the Promotion of Science (21K08628)
This publication has 38 references indexed in Scilit:
- Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosisCell Metabolism, 2022
- Bile duct ligation differently regulates protein expressions of organic cation transporters in intestine, liver and kidney of rats through activation of farnesoid X receptor by cholate and bilirubinActa Pharmaceutica Sinica B, 2022
- Influence of Liver Cirrhosis on Blood Glucose, Insulin Sensitivity and Islet Function in MiceThe American Journal of the Medical Sciences, 2021
- Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosisAdvanced Drug Delivery Reviews, 2021
- The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cellsEndocrinology, Diabetes & Metabolism, 2021
- System-wide Benefits of Intermeal Fasting by AutophagyCell Metabolism, 2017
- Hepatic transcriptomic and metabolic responses of hybrid striped bass (Morone saxatilis×Morone chrysops) to acute and chronic hypoxic insultComparative Biochemistry and Physiology Part D: Genomics and Proteomics, 2016
- Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: A placebo-controlled clinical trialHepatology, 2012
- Mitochondria: In Sickness and in HealthCell, 2012
- Animal models for the study of hepatic fibrosisBest Practice & Research Clinical Gastroenterology, 2011